The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials.
 
Jinbing Bai
No Relationships to Disclose
 
Monica Borges
No Relationships to Disclose
 
Felix Nguyen-Tan
No Relationships to Disclose
 
David Rosenthal
No Relationships to Disclose
 
Jimmy Caudell
No Relationships to Disclose
 
Maura Gillison
Consulting or Advisory Role - Abbvie; Adaptimmune; Aptitude Health; Axiom Biotechnologies; Bayer; Bicara Therapeutics; Bicara Therapeutics; BioNTech; BioNTech; BioNTech SE; Boxer Capital; Brightly Network; Bristol-Myers Squibb; Bristol-Myers Squibb/Roche; Caladrius Biosciences; Coherus Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; EMD Serono; EMD Serono; END Merck; Exelixis; Gilead Sciences; Guidepoint Global; Ipsen; Istari; ITeos Therapeutics; Journal of Clinical Oncology; Kura Oncology; LLX Solutions; LLX Solutions; Merck; Merus; Merus; Mirati Therapeutics; Nektar; OncLive; Pfizer; Seagen; Sensei Biotherapeutics; Shattuck Labs; Surface Oncology; Suzhou Liangyihui Network Technology; Takeda
Research Funding - Abbvie (Inst); Agenus (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Gilead Sciences (Inst); INVAX (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); NRG Oncology (Inst); Roche (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - PCT/US2022/023911 pending Board of Regents, The University of Texas System
 
Loren Mell
No Relationships to Disclose
 
Deborah Bruner
Employment - Emory University
Stock and Other Ownership Interests - Abbvie; Altria; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Pfizer; Procter & Gamble; Stryker; Viatris; Walgreens Boots Alliance
Honoraria - Alliance; American Society for Radiation Oncology; Memorial Sloan-Kettering Cancer Center; Oncology Nursing Society; Wilmot Cancer Center
Consulting or Advisory Role - University of Rochester
 
Katherine Yeager
No Relationships to Disclose
 
Ronald Eldridge
No Relationships to Disclose
 
Wade Thorstad
Employment - Elekta (I)
Travel, Accommodations, Expenses - Elekta (I)
 
Mary Jue Xu
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
 
Sara Medek
No Relationships to Disclose
 
Michelle Echevarria
No Relationships to Disclose
 
Musaddiq Awan
No Relationships to Disclose
 
Dong Shin
Research Funding - Loxo/Bayer; Sensei Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Update
 
Stephanie Pugh
Research Funding - Janssen (Inst); Pfizer (Inst)
 
Sue Yom
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst); Nanobiotix (Inst)